Combinations of gene deletions for live attenuated Shigella vaccine strains
AssigneeThe United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
InventorsMalabi M. Venkatesan, Ryan T. Ranallo, Shoshana Barnoy
Life of this patent
Estimating the term…
Abstract
Shigella vaccine strains whose primary attenuating feature is deletion of the virG(icsA) gene and additional two or more deletions in setAB(shET1), senA(shET2), senB(shET2-2), stxAB, and msbB2 genes. Thus, the vaccine strain will have three or more deletions in the identified genes, will be safer, and will reduce or eliminate symptoms of fever and diarrhea in humans. The following specific vaccine strains have been constructed: WRSS3 (ΔsenA, ΔsenB, ΔvirG, ΔmsbB2), WRSf2G15 (ΔvirG, ΔsetAB, ΔsenA, ΔsenB, ΔmsbB2), and WRSd5 (ΔvirG, ΔstxAB, ΔsenA, ΔsenB, ΔmsbB2).
Claims16
A live attenuated gut colonizing Shigella vaccine strain characterized as consisting of the following gene deletions or gene inactivations of virG(icsA), senA(shET2), and senB(shET2-2) in combination with one or more gene deletions or gene inactivations of genes selected from setAB(shET1), stxAB, and msbB2.
Dependencies are inferred from the claim text.